Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 9.77 |
| Open | 9.81 |
| Bid | 10.13 x 100 |
| Ask | 10.18 x 400 |
| Day's range | 9.71 - 10.24 |
| 52-week range | 3.84 - 14.75 |
| Volume | |
| Avg. volume | 427,414 |
| Market cap | 262.475M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.51 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.92 |
PR NewswireINOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- GuruFocus.com
Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.
PR NewswireINOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
